SCHEMBL2861409

SCHEMBL2861409

C=C(C)CCC/C=C(\C)COCCCC

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
LSS P48449 1/20 0.38
CES2 O00748 2/20 0.37
TSHR P16473 2/20 0.34
HPGD P15428 1/20 0.30
EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2861411 1.00 LSS (0.38) LSSCES2TSHRHPGDEPHX2
SCHEMBL2866064 0.92 LSS (0.33) LSSCES2
SCHEMBL2866063 0.92 LSS (0.33) LSSCES2
SCHEMBL2857316 0.84
SCHEMBL2857319 0.84
SCHEMBL2864372 0.81 TDP1 (0.39)
SCHEMBL2864374 0.81 TDP1 (0.39)
SCHEMBL1269879 0.77 KMT2A (0.31)
SCHEMBL1269881 0.77 KMT2A (0.31)
SCHEMBL2855424 0.75 LSS (0.51) LSSCES2TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728180-B2 Method for producing ethers KURARAY CO., LTD. (JP) 2010-06-01 US disclosed
US-20080262272-A1 Method For Producing Ethers KURARAY CO., LTD. (JP) 2008-10-23 US disclosed
CN-1972888-A Method for producing ethers KURARAY CO (JP) 2007-05-30 CN disclosed
EP-1760061-A1 METHOD FOR PRODUCING ETHERS KURARAY CO., LTD. (JP) 2007-03-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262272-A1 Method For Producing Ethers TELO2, PDS5A, TERT LSS 1302/4885CES2 2756/4885TSHR 657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.